Synthetic Triglyceride Shows Potential in Huntington Disease
The synthetic triglyceride triheptanoin may restore brain energy and decrease caudate atrophy in Huntington disease -- and improve motor function for up to a year.
Stay updated with breaking news from Wave Life Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The synthetic triglyceride triheptanoin may restore brain energy and decrease caudate atrophy in Huntington disease -- and improve motor function for up to a year.
First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating functional AAT protein Wave’s program in alpha-1 antitrypsin deficiency aims to correct the single base mutation in mRNA derived from the SERPINA1 Z allele, thereby addressing both lung and liver manifestations of the disease CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Na
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to give a presentation at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET. Dr. Bolno will provide a corporate update and discuss Wave’s pipeline programs, inclu...
Dive Brief: UniQure can begin treating patients with the highest dose of its experimental Huntington's disease gene therapy, announcing Thursday that clinical trial monitors found no safety concerns after reviewing data from the first 10 participants who received lower doses. The safety panel's go-ahead clears the way for the Massachusetts-based company to enroll another 16 patients. The trial is primarily assessing the safety of the gene therapy, called AMT-130, but will also measure biomarkers, cognition and motor function. Huntington's disease drug development has seen two major setbacks, ...
Hopes are high for a class of drug that could treat neurodegenerative conditions—but a recent clinical trial has brought the field up short